A phase 1 trial evaluating SENTI-202 demonstrated positive preliminary results in treating relapsed/refractory acute myeloid ...

TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the ...

The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA ...

The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ...

Dr. Hyung L. Kim discusses how the addition of cytoreductive nephrectomy to ICI therapy may affect survival and quality of ...

A chance meeting with my childhood friend reminded me — and others— that living with cancer means taking things one day at a time.

Sinai, Urology, located in Los Angeles, including professor; associate director, Urology Residency Training Program; chair, Department of Urology; co-medical director, Urologic Oncology Center; and ...

INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian ...